Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / draft-uspi-psoriasis-rev3.docx
draft-uspi-psoriasis-rev3.docx
Parties
HARKNESS LLP
Penterra Pharmaceuticals Corp
Callendar Baines Group LLC
Grange LLP
Dates
October 15, 2022
June 14, 2019
May 4, 2022
October 3, 2022
October 12, 2022
October 20, 2022
July 28, 2022
September 8, 2022
Amounts
Obligations
All data placeholders in this section (denoted by "[DATA PENDING]") must be resolved before the sNDA filing
All brackets marked "[DATA PENDING]" must be resolved prior to sNDA filing
Penterra received a deferral from the pediatric study requirement, which was granted on July 28, 2022, providing that pediatric study results must be submitted no later than 18 months after adult psoriasis approval